X-Linked Adrenoleukodystrophy: Overview and Prognosis as a Function of Age and Brain Magnetic Resonance Imaging Abnormality. A Study Involving 372 Patients
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The phenotypic expression of X-linked adrenoleukodystrophy (X-ALD) ranges from the rapidly progressive childhood cerebral form to the milder adrenomyeloneuropathy (AMN) in adults. It is not possible to predict phenotype by mutation analysis or biochemical assays. This study reports on 372 patients ranging in age from less than 3 years to adulthood, who have been followed at the Kennedy Krieger Institute. With the aim of determining whether a method could be developed to predict clinical course by analysis of data available at time of first contact, the patients were subdivided into 18 subgroups on the basis of age and the extent of brain magnetic resonance (MRI) abnormality utilizing the MRI scoring system devised by Loes et al. Scores to grade degree of neurologic and neuropsychologic impairment were also developed. There was strong correlation between MRI and the neurology and neuropsychology scores at baseline. Information based exclusively on age and MRI score at time of first contact was highly predictive of future clinical course and should aid the evaluation of the effects of bone marrow transplantation and the selection of patients for this procedure, as well as the evaluation of other therapies that may be developed in the future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both the Loes score and the neurologic function score have been validated for patients with adrenoleukodystrophy.”
From Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy (2024) · cites this paper as [18]
In the citing paper
“The most severe phenotype is an aggressive form of inflammatory demyelination called cerebral adrenoleukodystrophy (CALD) characterized by focal blood-brain barrier (BBB) disruption and leukocyte infiltration into the white matter (Fig. 1a, b)2.”
From Hematopoietic stem-cell gene therapy is associated with restored white matter microvascular function in cerebral adrenoleukodystrophy (2023) · cites this paper as [2]
In the citing paper
“Reductions in white matter CBF has also been found X-linked adrenoleukodystrophy (ALD), a disease caused by mutations in ABCD1, which encodes a peroxisomal membrane transporter protein, leading to accumulation of very long chain fatty acids in brain, spinal cord and adrenal glands (Moser et al., 2000).”
From The Pathobiology of Vascular Dementia (2013) · cites this paper as Moser et al., 2000
In the citing paper
“In its infantile form, the disease starts between 4 and 8 years of age and is characterized by a progressive cognitive decline associated with rampant inflammatory demyelination of the white matter (Moser et al., 2000).”
From The Pathobiology of Vascular Dementia (2013) · cites this paper as Moser et al., 2000
In the citing paper
“Reductions in white matter CBF has also been found X-linked adrenoleukodystrophy (ALD), a disease caused by mutations in ABCD1, which encodes a peroxisomal membrane transporter protein, leading to accumulation of very long chain fatty acids in brain, spinal cord and adrenal glands (Moser et al., 2000).”
From The Pathobiology of Vascular Dementia (2013) · cites this paper as Moser et al., 2000
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Cited by
The Pathobiology of Vascular Dementia
Iadecola, C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.008 · Cited by 1,857
“On the other hand, if the reduction in CBF is sustained and severe, ischemic stroke ensues (Moskowitz et al., 2010).”
Biochemistry of mammalian peroxisomes revisited
Wanders, R. J. A., & Waterham, H. R. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133329 · Cited by 995
Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy
Eichler, F., Duncan, C., Musolino, P. L., Orchard, P. J., De Oliveira, S., Thrasher, A. J., Armant, M., Dansereau, C., Lund, T. C., Miller, W. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700554 · Cited by 604
Self-citationMultiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions
Banwell, B., Ghezzi, A., Bar-Or, A., Mikaeloff, Y., & Tardieu, M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70242-9 · Cited by 394
Kemp, S., Pujol, A., Waterham, H. R., van Geel, B. M., Boehm, C. D., Raymond, G. V., Cutting, G. R., Wanders, R. J. A., & Moser, H. W. (2001) · Human Mutation · doi:10.1002/humu.1227 · Cited by 321
“Decision whether and when this therapy should be offered requires a great deal of clinical judgment [Moser et al., 2000; Moser et al., 2001].”
BackgroundSelf-citationAdrenoleukodystrophy: Incidence, new mutation rate, and results of extended family screening
Bezman, L., Moser, A. B., Raymond, G. V., Rinaldo, P., Watkins, P. A., Smith, K. D., Kass, N. E., & Moser, H. W. (2001) · Annals of Neurology · doi:10.1002/ana.101 · Cited by 324
Self-citationAnalysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy
Loes, D. J., Fatemi, A., Melhem, E. R., Gupte, N., Bezman, L., Moser, H. W., & Raymond, G. V. (2003) · Neurology · doi:10.1212/01.wnl.0000079050.91337.83 · Cited by 268
Self-citationGene therapy using haematopoietic stem and progenitor cells
Ferrari, G., Thrasher, A. J., & Aiuti, A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00298-5 · Cited by 254
Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil
Moser, H. W., Raymond, G. V., Lu, S.-E., Muenz, L. R., Moser, A. B., Xu, J., Jones, R. O., Loes, D. J., Melhem, E. R., Dubey, P., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1073 · Cited by 239
“This is clinically significant because brain MRI abnormalities have been shown to correlate with neurological and neuropsychological deficits and prognosis in ALD.(29) Despite the apparent bidirectional association between C26:0 levels and time to progression (Figure), our results imply an elevated risk of developing…”
BackgroundInfluentialSelf-citationTurk, B. R., Theda, C., Fatemi, A., & Moser, A. B. (2020) · International Journal of Developmental Neuroscience · doi:10.1002/jdn.10003 · Cited by 210
Peroxisomes, lipid metabolism, and peroxisomal disorders
Wanders, R. J. A. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.08.016 · Cited by 210
Metabolic and molecular basis of peroxisomal disorders: A review
Wanders, R. J. A. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.20661 · Cited by 173
Krivit, W. (2004) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0166-2 · Cited by 170
International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy
Engelen, M., van Ballegoij, W. J. C., Mallack, E. J., Van Haren, K. P., Köhler, W., Salsano, E., van Trotsenburg, A. S. P., Mochel, F., Sevin, C., Regelmann, M. O., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201374 · Cited by 156
“In boys and men with typical confluent white matter abnormalities on brain imaging— but no neurologic symptoms—cerebral ALD should still be considered as lesion development that may precede symptoms.(13) Peripheral neuropathy is a common feature of ALD but is rarely the presenting symptom.”
BackgroundSelf-citationRaymond, G. V., Aubourg, P., Paker, A., Escolar, M., Fischer, A., Blanche, S., Baruchel, A., Dalle, J.-H., Michel, G., Prasad, V., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.09.036 · Cited by 142
Self-citationMyelin lipid metabolism and its role in myelination and myelin maintenance
Barnes-Vélez, J. A., Aksoy Yasar, F. B., & Hu, J. (2023) · The Innovation · doi:10.1016/j.xinn.2022.100360 · Cited by 73
The peroxisomal ABC transporter family
Wanders, R. J. A., Visser, W. F., van Roermund, C. W. T., Kemp, S., & Waterham, H. R. (2006) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-006-0142-x · Cited by 129
Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy
Eichler, F., Duncan, C. N., Musolino, P. L., Lund, T. C., Gupta, A. O., De Oliveira, S., Thrasher, A. J., Aubourg, P., Kühl, J.-S., Loes, D. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400442 · Cited by 107
Self-citationNewborn Screening for X-Linked Adrenoleukodystrophy
Moser, A., Jones, R., Hubbard, W., Tortorelli, S., Orsini, J., Caggana, M., Vogel, B., & Raymond, G. (2016) · International Journal of Neonatal Screening · doi:10.3390/ijns2040015 · Cited by 106
Self-citationProton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy
Eichler, F. S., Barker, P. B., Cox, C., Edwin, D., Ulug, A. M., Moser, H. W., & Raymond, G. V. (2002) · Neurology · doi:10.1212/wnl.58.6.901 · Cited by 99
Self-citationOutcomes of Unrelated Umbilical Cord Blood Transplantation for X-Linked Adrenoleukodystrophy
Beam, D., Poe, M. D., Provenzale, J. M., Szabolcs, P., Martin, P. L., Prasad, V., Parikh, S., Driscoll, T., Mukundan, S., Kurtzberg, J., et al. (2007) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2007.01.082 · Cited by 83
Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients
Öz, G., Tkáč, I., Charnas, L. R., Choi, I., Bjoraker, K., Shapiro, E., & Rolf Gruetter, A. (2005) · Neurology · doi:10.1212/01.wnl.0000150906.52208.e7 · Cited by 95
Brain endothelial dysfunction in cerebral adrenoleukodystrophy
Musolino, P. L., Gong, Y., Snyder, J. M. T., Jimenez, S., Lok, J., Lo, E. H., Moser, A. B., Grabowski, E. F., Frosch, M. P., & Eichler, F. S. (2015) · Brain · doi:10.1093/brain/awv250 · Cited by 92
Current and Future Pharmacological Treatment Strategies in X‐Linked Adrenoleukodystrophy
Berger, J., Pujol, A., Aubourg, P. R., & Forss‐Petter, S. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00393.x · Cited by 102
Mallack, E. J., Turk, B. R., Yan, H., Price, C., Demetres, M., Moser, A. B., Becker, C., Hollandsworth, K., Adang, L., Vanderver, A., et al. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12356 · Cited by 79
Self-citationTanaka, K., Shimizu, T., Ohtsuka, Y., Yamashiro, Y., & Oshida, K. (2007) · Brain and Development · doi:10.1016/j.braindev.2007.02.005 · Cited by 77
Baba, Y., Ghetti, B., Baker, M. C., Uitti, R. J., Hutton, M. L., Yamaguchi, K., Bird, T., Lin, W., DeLucia, M. W., Dickson, D. W., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0046-z · Cited by 106
MRI and proton MRSI in women heterozygous for X-linked adrenoleukodystrophy
Fatemi, A., Barker, P. B., Uluğ, A. M., Nagae-Poetscher, L. M., Beauchamp, N. J., Moser, A. B., Raymond, G. V., Moser, H. W., & Naidu, S. (2003) · Neurology · doi:10.1212/01.wnl.0000059546.15529.cb · Cited by 59
Self-citationWeber, F. D., Wiesinger, C., Forss-Petter, S., Regelsberger, G., Einwich, A., Weber, W. H. A., Kohler, W., Stockinger, H., & Berger, J. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt645 · Cited by 63
MRI brain lesions in asymptomatic boys with X-linked adrenoleukodystrophy
Liberato, A. P., Mallack, E. J., Aziz-Bose, R., Hayden, D., Lauer, A., Caruso, P. A., Musolino, P. L., & Eichler, F. S. (2019) · Neurology · doi:10.1212/wnl.0000000000007294 · Cited by 69
Magnetization transfer MRI demonstrates spinal cord abnormalities in adrenomyeloneuropathy
Fatemi, A., Smith, S. A., Dubey, P., Zackowski, K. M., Bastian, A. J., van Zijl, P. C., Moser, H. W., Raymond, G. V., & Golay, X. (2005) · Neurology · doi:10.1212/01.wnl.0000164458.02141.06 · Cited by 64
Self-citationMoser, H. W., Raymond, G. V., Köehler, W., Sokolowski, P., Hanefeld, F. A., Korenke, G. C., Green, A., Loes, D. J., HUNNEMAN, D. H., Jones, R. O., et al. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-9072-3_47 · Cited by 68
Self-citationLeukodystrophies: recent developments in genetics, molecular biology, pathogenesis and treatment*
Berger, J., Moser, H. W., & Forss‐Petter, S. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200106000-00007 · Cited by 66
Self-citationAdrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor
Barendsen, R. W., Dijkstra, I. M. E., Visser, W. F., Alders, M., Bliek, J., Boelen, A., Bouva, M. J., van der Crabben, S. N., Elsinghorst, E., van Gorp, A. G. M., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00499 · Cited by 65
Adrenoleukodystrophy in female heterozygotes: underrecognized and undertreated
Jangouk, P., Zackowski, K. M., Naidu, S., & Raymond, G. V. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.11.001 · Cited by 63
Self-citationX‐linked adrenoleukodystrophy: Therapeutic approaches to distinct phenotypes
Mahmood, A., Dubey, P., Moser, H. W., & Moser, A. B. (2005) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2005.00447.x · Cited by 68
Self-citationMallack, E. J., Gao, K., Engelen, M., & Kemp, S. (2022) · Cells · doi:10.3390/cells11020283 · Cited by 60
“In childhood, 30–35% of boys will develop a fatal cerebral inflammatory disease (cerebral ALD) with a 50–60% total lifetime risk of developing cerebral disease [6,11,12].”
BackgroundEichler, F., Mahmood, A., Loes, D., Bezman, L., Lin, D., Moser, H. W., & Raymond, G. V. (2007) · Archives of Neurology · doi:10.1001/archneur.64.5.659 · Cited by 62
Self-citationTherapy of X-linked adrenoleukodystrophy
Moser, H. W. (2006) · NeuroRx · doi:10.1016/j.nurx.2006.01.004 · Cited by 66
Self-citationKruska, N., Schönfeld, P., Pujol, A., & Reiser, G. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.01.005 · Cited by 56
Pizcueta, P. M., Vergara, C., Emanuele, M., Vilalta, A., Rodríguez‐Pascau, L., & Martinell, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043201 · Cited by 59
N-acetyl-L-cysteine improves outcome of advanced cerebral adrenoleukodystrophy
Tolar, J., Orchard, P. J., Bjoraker, K., Ziegler, R. S., Shapiro, E., & Charnas, L. R. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705571 · Cited by 54
Schneider, J., Il'yasov, K. A., Boltshauser, E., Hennig, J., & Martin, E. (2003) · PubMed · Cited by 59
Therapy of X-linked adrenoleukodystrophy
Semmler, A., Köhler, W., Jung, H. H., Weller, M., & Linnebank, M. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.9.1367 · Cited by 53
Polgreen, L. E., Chahla, S., Miller, W., Rothman, S., Tolar, J., Kivisto, T., Nascene, D., Orchard, P. J., & Petryk, A. (2011) · European Journal of Pediatrics · doi:10.1007/s00431-011-1401-1 · Cited by 49
Ashrafi, M. R., & Tavasoli, A. R. (2017) · Brain and Development · doi:10.1016/j.braindev.2017.01.001 · Cited by 52
ABCD1 dysfunction alters white matter microvascular perfusion
Lauer, A., Da, X., Hansen, M. B., Boulouis, G., Ou, Y., Cai, X., Liberato Celso Pedrotti, A., Kalpathy-Cramer, J., Caruso, P., Hayden, D. L., et al. (2017) · Brain · doi:10.1093/brain/awx262 · Cited by 48
Haematopoietic stem cell transplantation in 12 patients with cerebral X-linked adrenoleukodystrophy
Baumann, M., Korenke, C., Weddige-Diedrichs, A., Wilichowski, E., Hunneman, D., Wilken, B., Brockmann, K., Klingebiel, T., Niethammer, D., Kühl, J., et al. (2003) · European Journal of Pediatrics · doi:10.1007/s00431-002-1097-3 · Cited by 47
“For longitudinal and interindividual analysis, 25 tests or subtests (Table 3) were selected which had been used consistently in all patients and which have shown to be sensitive to changes in patients with cerebral X-ALD [ 23 ,32] and have age related normative data available (T- and z-scores).”
BackgroundMethodLong-Term Follow-Up of Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy
Bougnères, P., Hacein-Bey-Abina, S., Labik, I., Adamsbaum, C., Castaignède, C., Bellesme, C., & Schmidt, M. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.053 · Cited by 45
“8,22,30,31 Indeed, among 14 boys with untreated c-ALD who showed gadolinium enhancement and, yet, no MFD like our patients, 12 developed MFD scores up to 4–6 within only 2 years, and 8 patients died within 5 years.”
Spectroscopic evidence of cerebral axonopathy in patients with “pure” adrenomyeloneuropathy
Dubey, P., Fatemi, A. S., Barker, P. B., Degaonkar, M. N., Tröger, M., Zackowski, K. M., Bastian, A. J., Smith, S. A., Pomper, M. G., Moser, H. W., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000149514.13580.84 · Cited by 47
Self-citationMallack, E. J., Turk, B. R., Yan, H., & Eichler, F. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0605-y · Cited by 45
Newborn screening for lysosomal storage disorders and other neuronopathic conditions
Matern, D., Oglesbee, D., & Tortorelli, S. (2013) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.1117 · Cited by 41
“Although hormone replacement therapy is mandatory in affected patients, it is well known that it affects neither the development nor the progression of neurological symptoms [Moser et al., 2000].”
BackgroundChiesa, R., Boelens, J. J., Duncan, C. N., Kühl, J.-S., Sevin, C., Kapoor, N., Prasad, V. K., Lindemans, C. A., Jones, S. A., Amartino, H. M., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005294 · Cited by 40
Self-citationRodríguez-Pascau, L., Vilalta, A., Cerrada, M., Traver, E., Forss-Petter, S., Weinhofer, I., Bauer, J., Kemp, S., Pina, G., Pascual, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc0555 · Cited by 40
Clinical and radiographic course of arrested cerebral adrenoleukodystrophy
Mallack, E. J., van de Stadt, S., Caruso, P. A., Musolino, P. L., Sadjadi, R., Engelen, M., & Eichler, F. S. (2020) · Neurology · doi:10.1212/wnl.0000000000009626 · Cited by 39
Hypoperfusion predicts lesion progression in cerebral X-linked adrenoleukodystrophy
Musolino, P. L., Rapalino, O., Caruso, P., Caviness, V. S., & Eichler, F. S. (2012) · Brain · doi:10.1093/brain/aws206 · Cited by 37
Seven-Tesla proton magnetic resonance spectroscopic imaging in adult X-linked adrenoleukodystrophy
Ratai, E., Kok, T., Wiggins, C., Wiggins, G., Grant, E., Gagoski, B., O’Neill, G., Adalsteinsson, E., & Eichler, F. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1488 · Cited by 37
“X -LINKED ADRENOLEUKODYStrophy (X-ALD) is a peroxisomal disorder that confers a lifelong risk for neurological deterioration.(1,2) In adulthood, male phenotypes can range from adrenomyeloneuropathy (AMN), a spastic paraparesis due to a chronic axonopathy of the spinal cord,(3) to adult cerebral ALD (ACALD), a rapidly…”
Singh, J., Khan, M., & Singh, I. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m017491 · Cited by 37
Successful donor engraftment and repair of the blood-brain barrier in cerebral adrenoleukodystrophy
Orchard, P. J., Nascene, D. R., Miller, W. P., Gupta, A., Kenney-Jung, D., & Lund, T. C. (2019) · Blood · doi:10.1182/blood-2018-11-887240 · Cited by 31
Cognitive Evaluation of Neurologically Asymptomatic Boys With X-linked Adrenoleukodystrophy
Cox, C. S., Dubey, P., Raymond, G. V., Mahmood, A., Moser, A. B., & Moser, H. W. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.69 · Cited by 33
Self-citationSalsano, E., Tabano, S., Sirchia, S. M., Colapietro, P., Castellotti, B., Gellera, C., Rimoldi, M., Pensato, V., Mariotti, C., Pareyson, D., et al. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-10 · Cited by 32
Sensorimotor Function and Axonal Integrity in Adrenomyeloneuropathy
Zackowski, K. M., Dubey, P., Raymond, G. V., Mori, S., Bastian, A. J., & Moser, H. W. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.74 · Cited by 31
Self-citationRai, S., Suresh, B., Bhat, I., Sekhar, M., & Chakraborti, S. (2013) · Journal of Pediatric Neurosciences · doi:10.4103/1817-1745.123661 · Cited by 32
Imaging in X-Linked Adrenoleukodystrophy
van de Stadt, S. I. W., Huffnagel, I. C., Turk, B. R., van der Knaap, M. S., & Engelen, M. (2021) · Neuropediatrics · doi:10.1055/s-0041-1730937 · Cited by 30
Bonaventura, E., Alberti, L., Lucchi, S., Cappelletti, L., Fazzone, S., Cattaneo, E., Bellini, M., Izzo, G., Parazzini, C., Bosetti, A., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2022.1072256 · Cited by 27
McKinney, A. M., Nascene, D. R., Miller, W. P., Eisengart, J. B., Loes, D. J., Benson, M., Tolar, J., Orchard, P. J., Ziegler, R. S., Zhang, L., et al. (2012) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3232 · Cited by 27
Self-citationLauer, A., Speroni, S. L., Choi, M., Da, X., Duncan, C., McCarthy, S., Krishnan, V., Lusk, C. A., Rohde, D., Hansen, M. B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37262-w · Cited by 26
Self-citationLate-Onset Neuroaxonal Leucoencephalopathy with Spheroids and Vascular Amyloid
Browne, L., Sweeney, B. J., & Farrell, M. A. (2003) · European Neurology · doi:10.1159/000072504 · Cited by 25
Research challenges in central nervous system manifestations of inborn errors of metabolism
Dickson, P., Pariser, A., Groft, S. C., Ishihara, R. W., McNeil, D. E., Tagle, D. A., Griebel, D. J., Kaler, S. G., Mink, J. W., & Shapiro, E. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.11.164 · Cited by 23
Awaya, T., Kato, T., Niwa, A., Hiramatsu, H., Umeda, K., Watanabe, K., Shibata, M., Yamanaka, Y., Maruya, E., Saji, H., et al. (2009) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2009.01188.x · Cited by 23
Magnetic resonance spectroscopy: A new guide for the therapy of adrenoleukodystrophy
Moser, H. W., & Barker, P. B. (2005) · Neurology · doi:10.1212/wnl.64.3.406 · Cited by 23
Self-citationNewborn Screening and Emerging Therapies for X-Linked Adrenoleukodystrophy
Moser, A. B., & Fatemi, A. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1585 · Cited by 22
Pediatric neurodegenerative white matter processes: leukodystrophies and beyond
Phelan, J. A., Lowe, L. H., & Glasier, C. M. (2008) · Pediatric Radiology · doi:10.1007/s00247-008-0817-x · Cited by 22
de Freitas, J. L., Filho, F. M. R., Sallum, J. M. F., França, M. C., Pedroso, J. L., & Barsottini, O. G. P. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.116620 · Cited by 20
The effect of bone marrow transplantation on oxidative stress in X-linked adrenoleukodystrophy
Rockenbach, F. J., Deon, M., Marchese, D. P., Manfredini, V., Mescka, C. P., Ribas, G. S., Habekost, C. T., de Castro, C. G., Jardim, L. B., & Vargas, C. R. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.03.019 · Cited by 22
Magnetic Resonance and Diffusion Tensor Imaging in Pediatric White Matter Diseases
Kim, M. J. J., Provenzale, J. M., & Law, M. (2006) · Topics in Magnetic Resonance Imaging · doi:10.1097/01.rmr.0000248665.84211.0f · Cited by 20
Endocrine dysfunction in adrenoleukodystrophy
Engelen, M., Kemp, S., & Eichler, F. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819973-2.00018-6 · Cited by 21
Schaller, J., Moser, H. W., Begleiter, M. L., & Edwards, J. G. (2007) · Genetic Testing · doi:10.1089/gte.2007.0001 · Cited by 23
Self-citationCorrelation of Neurodevelopmental Features and MRI Findings in Infantile Krabbe's Disease
Provenzale, J. M., Peddi, S., Kurtzberg, J., Poe, M. D., Mukundan, S., & Escolar, M. L. (2008) · American Journal of Roentgenology · doi:10.2214/ajr.07.3885 · Cited by 18
Presymptomatic Lesion in Childhood Cerebral Adrenoleukodystrophy: Timing and Treatment
Mallack, E. J., van Haren, K. P., Torrey, A. C., van de Stadt, S. I. W., Engelen, M., Raymond, G. V., Fatemi, A. S., & Eichler, F. (2022) · Neurology · doi:10.1212/wnl.0000000000200571 · Cited by 17
Self-citationEvaluation of Therapy of X-Linked Adrenoleukodystrophy
Moser, H. W., Fatemi, A. S., Zackowski, K. M., Smith, S., Golay, X., Muenz, L. R., & Raymond, G. V. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000021245.12181.90 · Cited by 17
Self-citationSener, R. N. (2002) · Magnetic Resonance Imaging · doi:10.1016/s0730-725x(02)00489-7 · Cited by 17
Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials.
Metovic, J., Li, Y., Gong, Y., & Eichler, F. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00443 · Cited by 16
“The US clinical trials for elivaldogene autotemcel (eli-cel) enrolled boys (cid:1) 17 years who presented with early symptomatic CALD, de fi ned as radiologic Loes score 0.5 to nine [89] and clinical neurologic functional scale (NFS) score (cid:1) 1 [90].”
MethodInfluentialPost‐transplant adaptive function in childhood cerebral adrenoleukodystrophy
Pierpont, E. I., McCoy, E., King, K. E., Ziegler, R. S., Shanley, R., Nascene, D. R., Raymond, G. V., Phelan, R., Lund, T. C., Orchard, P. J., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.526 · Cited by 16
Self-citationCognitive Functions in Adult‐Onset Phenotypes of X‐Linked Adrenoleukodystrophy
Schäfer, L., Roicke, H., Fischer, M., Sühnel, A., & Köhler, W. (2021) · Annals of Neurology · doi:10.1002/ana.26141 · Cited by 19
Turk, B. R., Theda, C., Fatemi, A. S., & Moser, A. B. (2019) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2019.11.002 · Cited by 19
Adrenoleukodystrophy in the era of newborn screening
Eng, L., & Regelmann, M. O. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000515 · Cited by 20
Hematopoietic Cell Transplantation for Storage Diseases
Peters, C. (2003) · Wiley eBooks · doi:10.1002/9780470987070.ch107 · Cited by 15
CHM mutation spectrum and disease: An update at the time of human therapeutic trials
Zeitz, C., Nassisi, M., Coriat, C., Andrieu, C., Boyard, F., Condroyer, C., Démontant, V., Antonio, A., Lancelot, M., Frederiksen, H. N., et al. (2021) · Human Mutation · doi:10.1002/humu.24174 · Cited by 14
ABCD1 mutations and phenotype distribution in Chinese patients with X-linked adrenoleukodystrophy
Niu, Y., Wang, N., & Wu, Z. (2013) · Gene · doi:10.1016/j.gene.2013.03.067 · Cited by 13
Mallack, E. J., Askin, G., van de Stadt, S. I. W., Caruso, P. A., Musolino, P. L., Engelen, M., Niogi, S. N., & Eichler, F. (2021) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7250 · Cited by 14
Dong, B., Lv, W., Xu, L., Zhao, Y., Sun, X., Wang, Z., Cheng, B., Fu, Z., & Wang, Y. (2022) · International Journal of Endocrinology · doi:10.1155/2022/5479781 · Cited by 14
Bamiou, D., Davies, R. A., Jones, S., Musiek, F. E., Rudge, P., Stevens, J., & LUXON, L. M. (2004) · Journal of the American Academy of Audiology · doi:10.3766/jaaa.15.2.5 · Cited by 13
Shah, N., & Singh, I. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9746-0 · Cited by 13
Lund, T. C., Ng, M., Orchard, P. J., Loes, D. J., Raymond, G. V., Gupta, A., Kenny-Jung, D., & Nascene, D. R. (2020) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2020.06.019 · Cited by 12
Self-citationMutation analysis of the ALD gene in seven Japanese families with X-linked adrenoleukodystrophy
Matsumoto, T., Tsuru, A., Amamoto, N., Shimizu, T., Kondoh, T., Saitoh, N., Tsujii, T., & Tamagawa, K. (2003) · Journal of Human Genetics · doi:10.1007/s100380300019 · Cited by 12
Hematopoietic stem cell transplantation in leukodystrophies
Sevin, C., & Mochel, F. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-99209-1.00017-x · Cited by 13
Pierpont, E. I., Isaia, A., McCoy, E., Brown, S. J., Gupta, A. O., & Eisengart, J. B. (2022) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12581 · Cited by 12
Inborn Errors of Metabolism Presenting in Childhood
Cakir, B., Tekşam, M., Kösehan, D., Akın, K., & Köktener, A. (2011) · Journal of Neuroimaging · doi:10.1111/j.1552-6569.2011.00575.x · Cited by 11
Furushima, W., Inagaki, M., Gunji, A., Inoue, Y., Kaga, M., & Mizutani, S. (2009) · Journal of Child Neurology · doi:10.1177/0883073808331354 · Cited by 11
Metadata
- Authors
- Moser, H. W., Loes, D. J., Melhem, E. R., Raymond, G. V., Bezman, L., Cox, C. S., & Lu, S.-E.
- Affiliations
- Kennedy Krieger Institute (US)
- Venue
- Neuropediatrics
- Publisher
- Georg Thieme Verlag KG
- Published
- 2000-12
- Volume
- 31
- Issue
- 5
- Pages
- 227-239
- ISSN
- 0174-304X (ISSN-L)
- 1439-1899
- OpenAlex
- W2048923486
- Cited by
- 210
- References
- 0
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 10 · 2023: 11 · 2022: 12 · 2021: 14 · 2020: 10 · 2019: 10 · 2018: 8 · 2017: 11 · 2016: 5 · 2015: 5 · 2014: 1 · 2013: 9 · 2012: 7
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuropediatrics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (M01 RR-00052, M01RR000052)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD-10981, P01HD010981)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
- Keywords
- X-linked adrenoleukodystrophy, prognosis, clinical course prediction, age of onset, adrenomyeloneuropathy, cerebral adrenoleukodystrophy, neurological deficit, bone marrow transplantation, patient selection
- MeSH terms
- Adrenoleukodystrophy, Adult, Age Factors, Brain, Child, Diagnosis, Differential, Drug Combinations, Erucic Acids, Female, Follow-Up Studies, Genotype, Humans, Infant, Newborn, Magnetic Resonance Imaging, Male, Phenotype, Prognosis, Prospective Studies, Sex Factors, Triolein, Bone Marrow Transplantation, Treatment Outcome, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.